17 results about "Myasthenias" patented technology

The application provides a cell fixing solution for a myasthenia gravis antibody spectrum (IgG) detection kit (cellular immunofluorescence method) and a product and application thereof, and relates to the technical field of in-vitro detection. The cell fixing solution provided by the application is composed of polyoxymethylene, formaldehyde, acetic acid, raffinose and a buffer solution, can effectively fix the cell morphology, maximally retains the natural spatial conformation and antigen epitope integrity of myasthenia gravis related antigens AChR, Titin, RyR1, MuSK and LRP4, reduces the problems of antigen denaturation, epitope shielding and protein loss in the fixing process, can efficiently and accurately realize the synchronous joint detection of various specific antibodies, and the myasthenia gravis antibody spectrum (IgG) detection kit (cellular immunofluorescence method) prepared by the application has stable detection results, and has important clinical application value and industrial popularization prospect.

This invention relates to the field of medical data mining technology, specifically to a system for assessing eye muscle fatigue in myasthenia gravis based on infrared thermal imaging. First, the degree of blood circulation impairment is determined based on the temperature changes of pixels in various directions within a speckled region. Then, based on the number of speckled regions and the concentration of hot spots, a speckled region influence value reflecting local blood circulation and metabolic abnormalities is determined. Next, combining the degree of blood circulation impairment, the speckled region influence value, and the speckled region distribution, a comprehensive reference degree of eye muscle fatigue is determined. Furthermore, considering the distribution of speckled regions under the influence of grease, the degree of blood circulation impairment, and the characteristic that the reference degree of eye muscle fatigue typically does not change, a corresponding grease influence value is determined. Thus, combining the reference degree of eye muscle fatigue and the grease influence value allows for a more accurate determination of the eye muscle fatigue assessment value, resulting in better assessment of eye muscle fatigue in myasthenia gravis based on this value.

The application discloses a benzofuran glycoside compound, a separation and extraction method thereof, a pharmaceutical composition and application, and the compound 1 is separated from a macleaya cordata extract. A benzofuran compound is obtained by separating and purifying a n-butanol part chemical component of a macleaya cordata root. The inhibitory activity of all separated compounds 1 on a target point cyclooxygenase-2 of an inflammatory related disease is tested, the compound 1 has good inhibitory activity on COX-2 enzyme, and the compound 1 has better binding energy with the target point protein. The compound also has good NLRP3 related inhibitory effect, can be used alone or in combination with other drugs to regulate NLRP3 related proteins, is used for treating NLRP3 related mediated diseases and / or diseases, and is used for preparing drugs for preventing or treating the diseases. The compound 1 also has better inhibitory effect on acetylcholinesterase, and can be used for treating diseases such as Alzheimer's disease, myasthenia gravis and Parkinson's disease.

The application discloses a protein for human P / Q type VGCC autoantibody detection and application, relates to the technical field of autoantibody detection, and the protein is a VGCC6 protein, and the amino acid sequence is shown as SEQ ID NO:6. In view of the clinical diagnosis demand of Lambert-Eaton myasthenic syndrome and other diseases related to the antibody, the protein provides strong support for early screening, diagnosis and disease condition monitoring of clinical diseases, fills the short board of the existing detection technology, and promotes the improvement of the diagnosis and treatment level of related autoimmune diseases.

This invention relates to a ventilation detection device for patients with myasthenia gravis based on testing and detection, comprising: a muscle strength monitoring module, including an electromyography (EMG) sensor for acquiring EMG signals and calculating a muscle strength index; a respiratory monitoring module, connected to a mechanical ventilation device, for acquiring the patient's respiratory rate, tidal volume, and inspiratory time parameters; a blood detection module for collecting blood samples from the patient and detecting the levels of inflammatory factors and anti-acetylcholine receptor antibodies in the blood; and a control module for receiving muscle strength index data, respiratory parameter change trend data, and blood detection data; when the muscle strength index is lower than a preset first threshold, the respiratory parameter change trend is inconsistent with a preset pattern, and the levels of inflammatory factors or anti-acetylcholine receptor antibodies in the blood are higher than a preset second threshold, patient-ventilator resistance is determined to exist during ventilation.

The present application relates to the technical field of motion trajectory tracking, in particular to a skeletal muscle motion trajectory tracking system for early screening of myasthenia gravis patients. The system comprises: acquiring position coordinates and motion trajectories of key skeletal muscle nodes; determining the abnormal degree of muscle strength efficiency according to the instantaneous motion state fluctuation and curvature distribution of the motion trajectories; acquiring the bending angle and time sequence electrical signals of the target muscle pair of the muscle with synergistic effect, and determining the degree of synergy breakdown according to the fluctuation correlation of the time sequence electrical signals and the bending angles of different muscles; combining the abnormal degree of muscle strength efficiency and the degree of synergy breakdown to determine the motion trajectory abnormality coefficient, and tracking and screening based on the motion trajectory abnormality coefficient. The present application can effectively capture the irregular transition characteristics from "steady state to tremor state" of intermittent myasthenia, and effectively improve the sensitivity of early myasthenia screening.

The present application relates to the use of chicoric acid in the preparation of a medicament for preventing and / or treating myasthenia gravis. Specifically, the present application provides the use of chicoric acid and pharmaceutically acceptable salts, esters, solvates, polymorphs or prodrugs thereof in the preparation of a medicament for preventing and / or treating myasthenia gravis. The present application focuses on the use of the compound chicoric acid in correcting the core immune imbalance of myasthenia gravis, Th17 / Treg cell balance, intervening from the upstream of the disease, and is expected to achieve the fundamental treatment of myasthenia gravis and more persistent efficacy.

Compositions of recombinant intravenous immunoglobulin (rIVIG) proteins and methods for purifying and using rIVIG proteins. The compositions comprise oligomeric Fc molecules that bind Fc receptors with high avidity. The rIVIG proteins are useful as immunomodulatory molecules to treat immune disorders, including autoimmune diseases, such as refractory immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, lupus, Graves' disease, Kawasaki disease, dermatomyositis, myasthenia gravis, Guillain-Barre syndrome, autoimmune hemolytic anemia, and other immune and inflammatory conditions. The rIVIG proteins are also useful as immunomodulatory agents for patients to reduce immune rejection of organ transplants, stem cell transplants, and bone marrow transplants. In addition, the present invention provides rIVIG proteins of non-human origin for use in veterinary immune disorders, such as canine rIVIG proteins for treating dogs with autoimmune hemolytic anemia, immune thrombocytopenic purpura, rheumatoid arthritis, or other canine immune disorders.

This invention provides a monoclonal antibody against the Agrin protein and its applications, belonging to the field of immunoassay technology. The monoclonal antibody is secreted by a hybridoma cell line with accession number CCTCC NO: C2025396 and specifically recognizes a key epitope in the Z8 region of the human Agrin protein. Based on this monoclonal antibody and / or the Agrin Z8 peptide, this invention constructs a kit for detecting anti-Agrin Z8 antibodies in the serum of patients with myasthenia gravis. The Agrin monoclonal antibody is used as a positive control or quantitative standard in this kit. Furthermore, this Agrin monoclonal antibody can be used to construct animal models of myasthenia gravis to study the pathogenesis of the disease. The Agrin monoclonal antibody provided by this invention has high specificity and high affinity, providing a key tool for the standardized diagnosis of myasthenia gravis and an effective means for studying its pathogenesis.

The application discloses a 3alpha-OH bufotalin compound, which has a general formula of C 24 H 32 The 3alpha-OH bufotalin compound can be used for preparing medicines for resisting tumors, treating cough, treating myasthenia gravis and reducing blood sugar.

The invention relates to the technical field of medicine information, and discloses a system and a method for accurately selecting tacrolimus treatment dosage of a myasthenia gravis patient. The method comprises the following steps: acquiring multi-cycle administration records and corresponding blood concentration of a patient to form an initial sequence; establishing a theoretical contribution degree matrix through lagging compensation, and reversely decomposing a pure single administration concentration curve; matching the curve with an individual pharmacokinetic template, and identifying an abnormal metabolic segment; and associating the same-period clinical records to generate clinical metabolism association pairs, establishing a mapping relation between concentration fluctuation and clinical symptoms, and classifying abnormal drug effect modes. According to the method, the independent metabolism trajectory of single administration can be analyzed from the mixed monitoring data, and the drug metabolism dynamics and the clinical effect are accurately associated, so that a technical basis is provided for realizing prospective individualized accurate administration.

The invention provides methods of using a population of CD19 CAR-expressing cells (for example, rapcabtagene autoleucel) for treating myasthenia gravis. Also disclosed are methods of making a population of CD19 CAR-expressing cells.

The present disclosure includes methods of treating 05-associated disease or disorder, such as myasthenia gravis, with a combination that includes an antibody or antigen-binding fragment thereof that binds specifically to C5 and a C5 iRNA which is a glycoconjugate that includes a ligand having terminal N-Acetylgalactosamine (GalNAc) residues and / or N-acetylglucosamine (GIcNAc) residues; or with the C5 iRNA monotherapy.